Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Entero Therapeutics, Inc.
Entero Therapeutics, Inc. News
Nov 15, 2024 - globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
Nov 15, 2024 - accesswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
Nov 14, 2024 - businesswire.com
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO
Nov 14, 2024 - accesswire.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Entero Therapeutics, Inc. Merger
Entero Therapeutics, Inc. Quantitative Score
About Entero Therapeutics, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Entero Therapeutics, Inc. Earnings & Revenue
Entero Therapeutics, Inc. Financials
Table Compare
Compare ENTO metrics with: | |||
---|---|---|---|
Earnings & Growth | ENTO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ENTO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ENTO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ENTO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Entero Therapeutics, Inc. Income
Entero Therapeutics, Inc. Balance Sheet
Entero Therapeutics, Inc. Cash Flow
Entero Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Entero Therapeutics, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Entero Therapeutics, Inc. Executives
Name | Role |
---|---|
Mr. James R. Sapirstein M.B.A., R.Ph. | Chief Executive Officer & Chairman |
Ms. Sarah Romano CPA | Chief Financial Officer |
Ms. Amy Chandler-Skerkis | Vice President of Regulatory Affairs, QA & Compliance |
Ms. Jennifer A. Sealey-Voyksner Ph.D. | Senior Vice President for Research & Development |
Mr. Martin Krusin M.B.A. | Senior Vice President of Corporate Development |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. James R. Sapirstein M.B.A., R.Ph. | Chief Executive Officer & Chairman | Male | 1961 | 906.2K |
Ms. Sarah Romano CPA | Chief Financial Officer | Female | 1980 | 624.88K |
Ms. Amy Chandler-Skerkis | Vice President of Regulatory Affairs, QA & Compliance | Female | 1968 | -- |
Ms. Jennifer A. Sealey-Voyksner Ph.D. | Senior Vice President for Research & Development | Female | -- | |
Mr. Martin Krusin M.B.A. | Senior Vice President of Corporate Development | Male | -- |
Entero Therapeutics, Inc. Insider Trades
Date | 9 Oct |
Name | Romano Sarah |
Role | Chief Financial Officer |
Transaction | Disposed |
Type | S-Sale |
Shares | 476 |
Date | 9 Aug |
Name | Ramdeen Timothy R. |
Role | Director |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 2 Jul |
Name | Romano Sarah |
Role | Chief Financial Officer |
Transaction | Disposed |
Type | S-Sale |
Shares | 621 |
Date | 2 Jul |
Name | SAPIRSTEIN JAMES |
Role | Chairman and CEO |
Transaction | Disposed |
Type | S-Sale |
Shares | 1289 |
Date | 11 Jun |
Name | KHOSLA CHAITAN PHD |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 24889 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
9 Oct | Romano Sarah | Chief Financial Officer | Disposed | S-Sale | 476 |
9 Aug | Ramdeen Timothy R. | Director | Disposed | 0 | |
2 Jul | Romano Sarah | Chief Financial Officer | Disposed | S-Sale | 621 |
2 Jul | SAPIRSTEIN JAMES | Chairman and CEO | Disposed | S-Sale | 1289 |
11 Jun | KHOSLA CHAITAN PHD | Director | Acquired | A-Award | 24889 |